
    
      This study is being conducted to help determine whether the addition of
      Interferon-alpha(α-IFN),which were determined sensitized the activity of Temozolomide(TMZ) in
      vivo and vitro, when given along with temozolomide during the monthly cycles that follow
      radiation, is able to delay tumor growth, shrink tumors, or impact how long people with newly
      diagnosed high-grade glioma. Four weeks after radiotherapy, newly diagnosed WHO III-IV glioma
      patients will be randomised into two groups: TMZ group or TMZ+ α-IFN groups.
    
  